Kimia Biosciences
Healthcare
530313 BSE
₹29.48
Close ·
- P/E
- 19.27
Close 4 Nov 2026 ₹29.48 −1.60 −5.15% 1Y
Start ₹31.08
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 25.10%
- Debt to Equity
- 1.94
- EPS (TTM)
- ₹1.53
- Book Value
- ₹3.75
- Market Cap
- —
- P/E (TTM)
- 19.27
- P/B
- 7.86
- ROE
- 53.70%
- Dividend Yield
- 0.00%
- EBITDA
- ₹15.90 Cr
- 52W High
- ₹43.28
- 52W Low
- ₹23.20
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
46 Average
Data confidence 100/100
Category scores
- Quality
- 55
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 47
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 28
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 27
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 32
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 53.6%
Weaknesses
4- Stock is trading at 8.54 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -2.84% over past five years.
- Tax rate seems low
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 5 | 2 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Strong Bearish
Bearish
12
Neutral
5
Bullish
2
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 42.50
- Neutral
- MACD (12,26,9)
- −0.43
- Bearish
- SMA (50)
- 30.36
- Bearish
- SMA (200)
- 31.86
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Zero base |
|---|---|
| 5Y | −2.87% |
| 3Y | −3.76% |
| 1Y | −3.36% |
| TTM | −6.73% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | +6.96% |
| 3Y | Turned to profit |
| 1Y | −30.00% |
| TTM | −18.02% |
Operating cash flow
| 10Y | Turned positive |
|---|---|
| 5Y | +12.89% |
| 3Y | Turned positive |
| 1Y | −47.62% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | No sales |
|---|---|
| 5Y | +6.15 pp |
| 3Y | +16.05 pp |
| 1Y | −4.64 pp |
| TTM | −3.31 pp |
Revenue by year
| Mar 2017 | ₹1.00 Cr |
|---|---|
| Mar 2018 | ₹76.00 Cr |
| Mar 2019 | ₹94.00 Cr |
| Mar 2020 | ₹106 Cr |
| Mar 2021 | ₹133 Cr |
| Mar 2022 | ₹125 Cr |
| Mar 2023 | ₹129 Cr |
| Mar 2024 | ₹105 Cr |
| Mar 2025 | ₹119 Cr |
| Mar 2026 | ₹115 Cr |
Net profit by year
| Mar 2017 | −₹1.00 Cr |
|---|---|
| Mar 2018 | ₹2.00 Cr |
| Mar 2019 | ₹4.00 Cr |
| Mar 2020 | ₹1.00 Cr |
| Mar 2021 | ₹5.00 Cr |
| Mar 2022 | −₹4.00 Cr |
| Mar 2023 | −₹9.00 Cr |
| Mar 2024 | −₹5.00 Cr |
| Mar 2025 | ₹10.00 Cr |
| Mar 2026 | ₹7.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.23 | 24.2 | 26.14 | 30.3 | 22.4 | 28.18 | 30.1 | 38.24 | 23.58 | 34 | 30.1 | 27.2 | 20.72 |
| Expenses | 25.87 | 26.16 | 27.19 | 26.14 | 18.69 | 24.81 | 25.1 | 30.06 | 21.05 | 31.48 | 23.54 | 24.54 | 18.37 |
| Operating Profit | −1.64 | −1.96 | −1.05 | 4.16 | 3.71 | 3.37 | 5 | 8.18 | 2.53 | 2.52 | 6.56 | 2.66 | 2.35 |
| OPM % | −6.77% | −8.1% | −4.02% | 13.73% | 16.56% | 11.96% | 16.61% | 21.39% | 10.73% | 7.41% | 21.79% | 9.78% | 11.34% |
| Other Income | 0.13 | 0.64 | 0.58 | 0.3 | 0.08 | 0.37 | 0.42 | 0.44 | 0.85 | −0.33 | 0.1 | 1.01 | 0.08 |
| Interest | 1.28 | 1.12 | 1.31 | 1.34 | 1.11 | 1.04 | 1.01 | 1.4 | 1.75 | 0.27 | 0.75 | 0.75 | 0.83 |
| Depreciation | 0.83 | 0.82 | 0.82 | 0.82 | 0.9 | 0.79 | 0.82 | 0.88 | 0.94 | 0.97 | 0.85 | 1.16 | 1.11 |
| PBT | −3.62 | −3.26 | −2.6 | 2.3 | 1.78 | 1.91 | 3.59 | 6.34 | 0.69 | 0.95 | 5.06 | 1.76 | 0.49 |
| Tax % | −25.14% | −25.15% | −25% | 22.17% | 19.66% | 15.71% | −27.3% | 68.61% | 13.04% | −7.37% | −7.71% | 78.98% | 26.53% |
| Net Profit | −2.71 | −2.44 | −1.95 | 1.8 | 1.44 | 1.61 | 4.57 | 1.99 | 0.6 | 1.02 | 5.44 | 0.37 | 0.36 |
| EPS (₹) | −0.57 | −0.52 | −0.41 | 0.38 | 0.3 | 0.34 | 0.97 | 0.42 | 0.13 | 0.22 | 1.15 | 0.08 | 0.08 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 105 | 119 | 115 | 112 |
| Expenses | 4 | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 133 | 105 | 99 | 101 | 98 |
| Operating Profit | −2 | −3 | −1 | 2 | 6 | 4 | 8 | 1 | −5 | 0 | 20 | 14 | 14 |
| OPM % | −110% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −56% | 3.2% | 6% | 4.2% | 6% | 0.5% | −3.9% | −0.5% | 17% | 12% | 13% |
| Other Income | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 2 | 1 |
| Interest | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 4 | 3 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 |
| PBT | −2 | −4 | −1 | 2 | 4 | 1 | 6 | −5 | −12 | −7 | 14 | 8 | 8 |
| Tax % | 1% | 0% | −8% | −4% | −1% | −13% | 8% | −26% | −25% | −26% | 29% | 12% | — |
| Net Profit | −2 | −4 | −1 | 2 | 4 | 1 | 5 | −4 | −9 | −5 | 10 | 7 | 7 |
| EPS (₹) | −2.3 | −5.48 | −1.26 | 2.26 | 2.64 | 0.3 | 1.08 | −0.78 | −1.98 | −1.12 | 2.03 | 1.57 | 1.53 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | −7 | −11 | −12 | 0 | 4 | 9 | 14 | 10 | 1 | −4 | 5 | 13 |
| Borrowings | 1 | 7 | 14 | 34 | 31 | 34 | 45 | 41 | 53 | 44 | 33 | 35 |
| Other Liabilities | 4 | 1 | 3 | 22 | 29 | 38 | 43 | 54 | 63 | 56 | 68 | 51 |
| Total Liabilities | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 111 | 103 |
| Fixed Assets | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 32 | 33 | 37 |
| CWIP | 0 | 0 | 3 | 2 | 2 | 6 | 6 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1 | 1 | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 68 | 78 | 66 |
| Total Assets | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 111 | 103 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | −6 | −1 | −7 | −3 | 0 | 6 | 8 | −7 | 15 | 21 | 11 |
| Investing | 0 | 0 | −6 | −2 | −2 | −9 | −14 | −1 | −3 | −1 | −5 | −8 |
| Financing | 0 | 6 | 7 | 10 | 4 | 8 | 8 | −8 | 10 | −13 | −17 | −3 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | −6 | −7 | −10 | −5 | −9 | −8 | 6 | −10 | 13 | 17 | 3 |
| CFO/OP | −2 | 177 | 85 | −287 | −45 | 5 | 71 | 1,281 | 136 | −3,021 | 105 | 76 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | — | 20 | 141 | 113 | 128 | 115 | 88 | 87 | 96 | 113 | 93 |
| Inventory Days | 50 | — | 615 | 59 | 83 | 92 | 89 | 146 | 183 | 149 | 178 | 137 |
| Days Payable | 667 | — | 511 | 120 | 91 | 121 | 116 | 159 | 177 | 194 | 260 | 220 |
| Cash Conversion Cycle | −560 | — | 124 | 80 | 105 | 100 | 88 | 76 | 93 | 51 | 31 | 10 |
| Working Capital Days | −530 | — | −1,358 | 48 | 62 | 73 | 53 | 31 | 16 | −30 | −22 | 5 |
| ROCE % | −127% | −188% | −10% | 10% | 16% | 9% | 16% | −2% | −12% | −4% | 42% | 25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kimia Biosciences insights
64 extracted metrics across FY10–FY27.
Documents
- 29 May 2026
- General announcements 12 Oct 2026
Frequently Asked Questions about Kimia Biosciences
What does Kimia Biosciences Ltd do?
Incorporated in 1993, Kimia Biosciences Ltd is in the business of manufacturing and sale pharmaceutical products
Where is Kimia Biosciences Ltd (KIMIABL) listed?
Kimia Biosciences Ltd trades under code 530313 on the BSE.
Which sector does Kimia Biosciences Ltd belong to?
Kimia Biosciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Kimia Biosciences Ltd?
Kimia Biosciences Ltd trades at a PE ratio of 19.27 as of 4 Nov 2026, on earnings per share of ₹1.53, against a book value of ₹3.75 per share.
What is the 52-week high and low of Kimia Biosciences Ltd?
Over the last 52 weeks Kimia Biosciences Ltd has traded between ₹23.2 and ₹43.28 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Kimia Biosciences Ltd?
Kimia Biosciences Ltd reported a return on equity of 53.70%. Its debt-to-equity ratio is 1.94.
Company Information
Incorporated in 1993, Kimia Biosciences Ltd is in the business of manufacturing and sale pharmaceutical products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530313.md for Kimia Biosciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.